52nd week of 2014 patent applcation highlights part 40 |
Patent application number | Title | Published |
20140377147 | CHROMATOGRAPHY PIPETTE TIP - Chromatography pipette tip having a first vessel and a second vessel which is open at two opposite ends and which, in each instance, has a bottom orifice via which a sample liquid can either be sucked in or expelled. The two vessels are fluidically and sealably connected to one another. A reaction matrix is arranged in one of the two vessels, through which reaction matrix the sample liquid is pushed by means of a pipettor to which the chromatography pipette tip is connected when used as intended. The sample liquid is drawn in and dispensed in opposite directions by the chromatography pipette tip and flows through the reaction matrix only in one direction. | 2014-12-25 |
20140377148 | DEVICE AND METHOD FOR HANDLING BIOLOGICAL TISSUES - A tissue handling device is disclosed. A tissue collecting device is disclosed. A cassette for handling biological tissues is disclosed. A tissue dyeing device is disclosed. A method for handling biological tissues is disclosed. A method for dyeing biological tissues is disclosed. | 2014-12-25 |
20140377149 | REAGENT VESSEL AND KIT THEREOF - The present invention is related to a reagent vessel, comprising: at least one first tube and at least one second tube, wherein second tube has a section area of the opening greater than one of the bottom. A kit for a reagent vessel is also provided herein, comprising: the reagent vessel and a stirrer jacket, wherein the section area ratio value for the bottom of the second tube to the stirrer jacket is 1.1 to 3.5. According to the present invention, an optimum efficiency for the stirrer jacket will be achieved, and a high capacity of the operational volume will be maintained thereby. | 2014-12-25 |
20140377150 | SCANDIUM EXTRACTION METHOD - Provided is a method for selectively extracting and inexpensively recovering scandium from an acidic solution containing calcium, magnesium, and scandium. The scandium extraction method according to the present invention involves subjecting an acidic solution containing calcium, magnesium, and scandium to solvent extraction using an extraction agent consisting of an amide derivative represented by the general formula below. In the formula, R | 2014-12-25 |
20140377151 | PROCESS FOR RECOVERY OF COBALT, RUTHENIUM, AND ALUMINUM FROM SPENT CATALYST - A method for recovering cobalt, ruthenium, and aluminum from spent Co—Ru/Al | 2014-12-25 |
20140377152 | COPPER RECOVERY APPARATUS AND COPPER RECOVERY METHOD - According to one embodiment, a copper recovery apparatus includes a precipitation tank configured to precipitate copper hydroxide grains in water, a filter aid supplier, a mixing tank configured to mix the filter aid with a water to produce a suspension, a separator provided with a filter, a line configured to supply the suspension to the separator, thereby forming a precoat layer formed of the filter aid on the filter, a separation tank configured to receive the detached matter of the precoat layer discharged together with the detaching water from the separator to magnetically separate copper hydroxide grains and filter aid, a line configure to discharge and recover the detaching water from the separation tank, and a line configured to return the separated filter aid to the filter aid supplier from the separation tank. | 2014-12-25 |
20140377153 | METHOD FOR PREPARATION OF HIGH PURITY,CRYSTALLINE COBALT NITRATE FROM SPENT COBALT/SILICA CATALYST - A method for preparing crystalline cobalt nitrate. The method includes: 1) calcining a spent Co/SiO | 2014-12-25 |
20140377154 | LITHIUM RECOVERY METHOD - To provide a lithium recovery method which is capable of efficiently recovering lithium without containing impurities, such as phosphorus and fluorine. In the present invention, an alkali is added to a discharge liquid and/or a cleaning liquid containing lithium discharged in a process of recovering valuable metals from a lithium ion battery, an acidic solvent extractant is caused to be in contact with the discharge liquid and/or the cleaning liquid under a condition of pH 9 or less and a temperature of 0 to 25° C. and lithium ions are extracted, and the acidic solvent extractant having extracted the lithium ions is caused to be in contact with an acid solution of pH 3 or less and the lithium ions are stripped. | 2014-12-25 |
20140377155 | PROCESS FOR IN-SITU PRODUCTION OF LOW DISSOLVED HYDROGEN SULFIDE, DEGASSED, SULFUR FROM CLAUS SULFUR RECOVERY - A process of producing degassed liquid sulfur within a vertical sulfur condenser may include providing a plurality of condenser tubes within an external casing; submerging exit ends of the plurality of condenser tubes within a liquid reservoir resulting in submerged exit ends of the plurality of condenser tubes; passing the Claus process gas into an inlet end of the plurality of condenser tubes; condensing the Claus process gas within the condenser tubes to produce condensed Claus process gas within the plurality of condenser tubes; and collecting the condensed Claus process gas in the liquid reservoir upon exiting of the condensed Claus process gas at an exit end of the plurality of condenser tubes. The process may further include converting hydrogen sulfide by the Claus reaction 2H | 2014-12-25 |
20140377156 | Selectively CO2-Permeable Membrane, Method for Separating CO2 from Mixed Gas, and Membrane Separation Equipment - Disclosed is a CO | 2014-12-25 |
20140377157 | METHOD AND DEVICE FOR PRODUCING NITRIC ACID - A process is described for startup and/or shutdown of a plant for preparation of nitric acid from ammonia and oxygenous gas by the single pressure or dual pressure process, in which the ammonia used is oxidized by means of compressed process air over a catalyst, said process air having been compressed in at least one compressor ( | 2014-12-25 |
20140377158 | CHEMICAL LOOPING INTEGRATION WITH A CARBON DIOXIDE GAS PURIFICATION UNIT - A chemical looping system that contains an oxidizer and a reducer is in fluid communication with a gas purification unit. The gas purification unit has at least one compressor, at least one dryer; and at least one distillation purification system; where the gas purification unit is operative to separate carbon dioxide from other contaminants present in the flue gas stream; and where the gas purification unit is operative to recycle the contaminants to the chemical looping system in the form of a vent gas that provides lift for reactants in the reducer. | 2014-12-25 |
20140377159 | DISPERSION METHOD - A method for producing a solution of dispersed graphenes comprising contacting graphite having a dimension in the a-b plane of 10 μm or less with an electronic liquid comprising a metal and a polar aprotic solvent, and solutions of dispersed graphenes which may be obtained by such a method are described. | 2014-12-25 |
20140377160 | COMBUSTION SYNTHESIS OF GRAPHENE AND CARBONOUS NANOMATERIALS - The invention provides methods for the combustion synthesis (CS) of graphene by a novel exothermic self-sustained reaction between a refractory ceramic compound and a carbon-containing polymer under an inert gas atmosphere. The synthesis of graphene was confirmed by both transmission electron microscopy and Raman spectroscopy. The graphene produced has very low (<1 wt. %) oxygen content. Fluorocarbon gases released due to decomposition of the carbon-containing polymer in the combustion wave can reduce the ceramic to a gas and mesoporous carbon particles and graphene layers. The method does not require an external energy source because it occurs in a self-sustained synergetic manner after ignition. The methods are flexible in terms of tuning the synthesis conditions for desired products, and the method can be scaled to provide kilogram quantities. | 2014-12-25 |
20140377161 | METHOD FOR PRODUCING FLAKE GRAPHITE, AND FLAKE GRAPHITE - There is provided a method for producing relatively easily handleable exfoliated graphite by exfoliating graphite without complicated steps, and exfoliated graphite obtained by the method. A method for producing exfoliated graphite, comprising steps of preparing a composition which comprises graphite or primary exfoliated graphite and a polymer and in which the polymer is fixed to the graphite or primary exfoliated graphite; and pyrolyzing the polymer contained in the composition to exfoliate the graphite or primary exfoliated graphite and remove the polymer by pyrolysis. | 2014-12-25 |
20140377162 | Method of Forming a Gypsum Based Product - A method of forming a gypsum based product is disclosed. The method comprises the steps of: calcining a mixture of water and gypsum under conditions of raised temperature and pressure within a vessel to produce an alpha-hemihydrate slurry therein; passing the alpha-hemihydrate slurry from the vessel to a mixer for mixing with additional water to produce a settable slurry, which is arranged to set to form the gypsum based product. | 2014-12-25 |
20140377163 | METHOD AND APPARATUS FOR GENERATING MERCURY (II) SULFIDE FROM ELEMENTAL MERCURY - An approach is provided for generating red mercury (II) sulfide from elemental mercury. Elemental mercury is combined with sulfur and heated until vaporized. At least a portion of the elemental mercury reacts with the vaporized sulfur to form the mercury (II) sulfide. Un-reacted elemental mercury is drawn off and condensed by a condenser. | 2014-12-25 |
20140377164 | PROCESS FOR IN-SITU PRODUCTION OF LOW DISSOLVED HYDROGEN SULFIDE, DEGASSED, SULFUR FROM CLAUS SULFUR RECOVERY - A process of producing degassed liquid sulfur within a horizontal sulfur condenser may include condensing a portion of a Claus process gas introduced into a condenser tube to produce liquid sulfur; creating first and second chambers above a liquid sulfur reservoir with a baffle; passing the liquid sulfur and the Claus process gas into the first chamber; forcing the Claus process gas from the liquid reservoir within the first chamber to the second chamber; causing a chemical reaction between dissolved hydrogen sulfide in the liquid sulfur and sulfur dioxide from the Claus process gas on a catalyst to produce elemental sulfur and reducing the dissolved H | 2014-12-25 |
20140377165 | PROCESS FOR DEGASSING CONDENSED SULFUR FROM A CLAUS SULFUR RECOVERY SYSTEM - A process of producing degassed liquid sulfur using process gas containing H2S to agitate the liquid sulfur being degassed while in contact with a degassing catalyst. Process gas is less costly and less complicated and quickly accomplishes substantial degassing rendering the liquid sulfur much safer in storage and transportation. | 2014-12-25 |
20140377166 | SYSTEMS AND METHODS FOR REMOVING FINELY DISPERSED PARTICULATE MATTER FROM A FLUID STREAM - Disclosed are methods of removing particulate matter from a wastewater stream, comprising providing an activating agent capable of being affixed to the particulate matter in the wastewater stream; affixing the activating agent to the particulate matter to form activated particles residing in the wastewater stream; processing the activated particles in a thickener device to produce a population of thickened flocs in the fluid stream, wherein the thickened flocs comprise the particulate matter; contacting the thickened flocs with a re-activating agent to form re-activated particles comprising the particulate matter; providing a population of tether-bearing anchor particles, wherein the tether-bearing anchor particles have an affinity for the re-activated particles; attaching the tether-bearing anchor particles to the re-activated particles to form removable complexes that comprise the particulate matter, and removing the removable complexes, thereby removing the particulate matter from the wastewater stream. | 2014-12-25 |
20140377167 | METHOD FOR STARTING UP AN ELECTROLYZER - A method is provided for running up/starting up an electrolysis device ( | 2014-12-25 |
20140377168 | PHARMACEUTICAL GELS AND METHODS FOR DELIVERING THERAPEUTIC AGENTS TO A SITE BENEATH THE SKIN - Pharmaceutical gels and methods for delivering a therapeutic agent to a target tissue site beneath the skin of a patient are provided, the gel being capable of adhering to the target tissue site and comprising one or more biodegradable depots containing an effective amount of the therapeutic agent. In various embodiments, the gel is sprayable and hardens after contacting the target tissue site. | 2014-12-25 |
20140377169 | Automated synthesis device to produce Re-188-Liposome and method thereof - An automated synthesis device to produce Re-188-BMEDA solution including: a plurality of reagent vials, three-way solenoid valves, gel filtration columns and micro pumps, and a reaction vial, a product vial, a temporary storage vial, a filter membrane, and a waste vial, wherein the plurality of reagent vials include first reagent vial and second reagent vials being connected to the reaction vial through first micro pump, the third reagent vial and fourth reagent vial being connected to the reaction vial through second micro pump, fifth reagent vial being connected to the reaction vial through third micro pump, and sixth reagent vial being connected to the temporary storage vial through fourth micro pump, wherein the reaction vial is connected to the plurality of gel filtration columns through the micro-pump, respectively. The automated synthesis device is operable with program to upgrade yield and avoid contamination. | 2014-12-25 |
20140377170 | VIRION-DERIVED NANOSPHERES FOR SELECTIVE DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS TO CANCER CELLS - The invention relates to methods for producing papilloma-derived nanosphere particles that contain therapeutic, diagnostic, or other agents. The invention also provides nanosphere particle preparations that are useful for selectively delivering therapeutic, diagnostic, and/or other agents to cancer cells of subjects without eliciting a serotype-specific immunogenic response in the subjects. | 2014-12-25 |
20140377171 | Imaging and Treatment of Neuroendocrine Tumors with Glucose - Dependent Insulinotropic Polypeptide or Analogues or Antagonists Thereof - The invention relates to a method of imaging pancreatic β-cells, endocrine gastroenteropancreatic tumors and bronchial and thyroid neuroendocrine tumors and a method of treating endocrine gastroenteropancreatic tumors and bronchial and thyroid neuroendocrine tumors by targeting of glucose-independent insulinotropic polypeptide receptors (GIP receptors). Compounds considered are GIP or a GIP analog, each carrying a radionuclide, optionally complexed through a chelator. Non-radioactive GIP receptor antagonists as such are also considered in the long-term treatment of the mentioned tumors. The invention also relates to the use of a combination of GIP or a GIP analog, each carrying a radionuclide, with a GLP-1 agonist and/or somatostatin analogs, also carrying a radionuclide. | 2014-12-25 |
20140377172 | Novel Antibody Recognizing a Small Subset of Human Hematopoietic Cells - The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. In one embodiment, a monoclonal antibody, MG1, is provided. This antibody is useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation, genetic therapy, and in treating other diseases of the hematopoietic system. Cell suspensions containing MG1 | 2014-12-25 |
20140377173 | Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic Cancer - Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer. | 2014-12-25 |
20140377174 | METHOD FOR PREPARING CELL TARGETING CONJUGATES, AND THE COMPLEXES OBTAINED - A first aspect of the disclosure relates to a method for preparing cell-targeting conjugates by coupling at least one functional moiety, such as a therapeutic compound, diagnostic compound or chelating agent to a targeting moiety. A second aspect of this disclosure relates to the cell-targeting conjugates obtainable with this method. A third aspect of the disclosure described herein relates to pharmaceutical compositions comprising the cell-targeting conjugates. | 2014-12-25 |
20140377175 | CHEMICALLY-LINKED NANOPARTICLES - Provided herein are compositions and methods of preparing nanoparticle aggregates. | 2014-12-25 |
20140377176 | Functionalised silicon nanoparticles - The present invention is related to silicon nanoparticles, a pharmaceutical composition comprising silicon nanoparticles, a method for synthesis of the silicon nanoparticles and their use for in vivo diagnostics, visualization of drug delivery or staining of cells, biological processes or pathways. The silicon nanoparticles are characterised that they comprise a silicon core of a size of 1 to 10 nm and are terminated with allylamine or poly(allylamine) comprising up to 10 allylamine groups. | 2014-12-25 |
20140377177 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of | 2014-12-25 |
20140377178 | RADIOFLUORINATION METHOD - The present invention relates to a method of labelling biological molecules with | 2014-12-25 |
20140377179 | COMPOSITIONS AND METHODS FOR DELIVERING INHIBITORY OLIGONUCLEOTIDES - The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, in delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject. | 2014-12-25 |
20140377180 | PHOTOACOUSTIC CONTRAST AGENT HAVING LIPID PARTICLE CONTAINING SILICON NAPHTHALOCYANINE ANALOG - A conventional silicon naphthalocyanine-containing liposome is required to incorporate a dye dispersed therein for use in photodynamic therapy, and is thus low in dye content and also low in photoacoustic signal. According to a lipid particle containing a silicon naphthalocyanine analog, in which the ratio A/B of an absorption coefficient A at a first absorption local maximum to an absorption coefficient B at a second absorption local maximum in a range from 700 nm to 800 nm is 5.0 or less, the dye content in the lipid particle can be increased and the photoacoustic signal intensity can be improved. | 2014-12-25 |
20140377181 | MOLECULES WITH EXTENDED HALF-LIVES, COMPOSITIONS AND USES THEREOF - The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules. | 2014-12-25 |
20140377182 | MULTICELLULAR COMPOSITIONS OF PLURIPOTENT HUMAN EMBRYONIC STEM CELLS AND CANCER CELLS - Methods are provided for producing novel multicellular compositions comprising cancer cells together with pluripotent human stem cells, which are capable of proliferating and differentiating into various normal cell lines and tissue structures. These novel multicellular compositions are useful for investigating the properties of cancer cells in a normal human tissue microenvironment, and for studying interventions that will modulate these properties including devising, testing and screening therapeutic drugs. | 2014-12-25 |
20140377183 | METHODS, SYSTEMS, AND DEVICES FOR AN INVERTEBRATE MODEL OF TRAUMATIC BRAIN INJURY - Described herein are methods, systems, and devices for identifying agents and genetic pathways that modulate the effects of traumatic brain injury (TBI) in invertebrate model systems having a brain, e.g., | 2014-12-25 |
20140377184 | Methods and Compositions Related to Targeting Tumors and Wounds - Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to tumors, sties of injury and blood clots in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tumors, sites of injury and blood clots. | 2014-12-25 |
20140377185 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS - The invention encompasses compositions containing an iodinated contrast agent and a substituted cyclodextrin wherein the cyclodextrin stabilizes the contrast agent against degradation by ultraviolet or visible light exposure. | 2014-12-25 |
20140377186 | MICROBUBBLE ULTRASOUND CONTRAST AGENT FOR EXTERNAL USE - A microbubble ultrasound contrast agent for external use is provided. The microbubble ultrasound contrast agent applied externally can safely and efficiently enhance the permeation and absorption of the drug or small molecules in the local region of the body surface. | 2014-12-25 |
20140377187 | Embolizing Sclerosing Hydrogel - A sclerosing embolizing hydrogel comprising from about 0.1% by weight to about 4.0% by weight of chitosan; from about 0.01 M to about 1 M of hydrochloric acid; from 0% by volume to about 40% by volume of iopamidol; from 0.5% by weight to about 25% by weight of β-glycerophosphate disodium salt; and from about 0.05% by weight to about 4% by weight of sodium tetradecyl sulphate. Also a kit for synthesizing the hydrogel and a method using the hydrogel to treat a vascular defect in a subject. | 2014-12-25 |
20140377188 | Oral Composition Indicative Of Proper Tooth Cleaning - The present invention provides an oral care composition, containing at least 0.5% by weight of silica agglomerates, wherein each of the silica agglomerates has: (i) an overall particle size from 200 μm to 2000 μm, and (ii) a crush strength from 0.1N to 5N. The silica particles that make up the silica agglomerate can have an average particle size from 1 μm to 50 μm. The composition can have a viscosity from 10 to 90 BKU. The present invention also provides a method of encouraging proper tooth cleaning by administering the oral care composition of the present invention to a subject's tooth surface. The present invention further provides the use of a silica agglomerate in manufacturing an oral care composition for encouraging proper tooth cleaning | 2014-12-25 |
20140377189 | PULMONARY ADMINISTRATION OF ROTIGOTINE - Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a stable solution formulation of rotigotine that is suitable for administration via oral inhalation. Such methods and compositions are useful in the treatment or amelioration of one or more Parkinson's disease symptom(s). | 2014-12-25 |
20140377190 | COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS - Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium. | 2014-12-25 |
20140377191 | Toothpaste Compositions with Reduced Abrasivity - Toothpaste compositions are disclosed. The toothpaste composition comprises a binder; a surface active agent; an abrasive; a humectant; and water; in which: (1) the abrasive is silica, the composition additionally comprises a silica thickener, and the composition comprises 1 to 7 wt % of the silica thickener, less than 15 wt % of the silica abrasive, 45 to 70 wt % water, 0.8 to 3.0 wt % of a surface active agent; 0.05 to 3.0 wt % the binder; or (2) the abrasive is silica, the composition additionally comprises a silica thickener, the composition comprises 2 to 22 wt % total silica, 0.8 to 3.0 wt % of a surface active agent; 0.05 to 3.0 wt % the binder, and the composition additionally comprises about 0.1 to 8.0 wt % of non-colloidal microcrystalline cellulose, colloidal microcrystalline cellulose, or a mixture thereof; or (3) the binder is a calcium based abrasive, the binder is a cellulose gum, and the composition comprises 25 to 55 wt % of the calcium based abrasive, 35 to 60 wt % water, 0.8 to 3.0 wt % of the surface active agent, and 1.0 to 3.0 wt % of the binder. | 2014-12-25 |
20140377192 | ORAL CARE COMPOSITIONS - Described herein are oral care compositions comprising an effective amount of an enzyme cocktail, wherein the enzyme cocktail comprises an alkaline protease and a second enzyme selected from cellulase, α-glucanase, and combinations thereof, in an orally acceptable carrier, together with methods of making and using the same. | 2014-12-25 |
20140377193 | Oral Care Compositions - Oral care compositions comprising a crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, together with an ethylene oxide-propylene oxide block copolymer. Some embodiments further comprise a calcium abrasive, e.g. calcium pyrophosphate or calcium carbonate, and some may have less than 3% water. | 2014-12-25 |
20140377194 | Stain-Proof Oral Care Composition - The present invention provides an oral care composition containing (a) a zinc citrate; and (b) a surface-active organophosphate compound. The present invention also relates to a method of preventing a stain from depositing on a tooth surface or other oral surfaces. The present invention further relates to a method of demonstrating stain-proof efficacy of an oral care composition, as well as a demonstration product comprising a substrate coated with hydroxyapatite. | 2014-12-25 |
20140377195 | POLYMER COMPOSITION CONTAINING NATURAL BIOACTIVE PRINCIPLES FOR USE IN PHARMACEUTICAL AND COSMETIC FORMULATIONS - The present invention relates to a polymer composition containing natural bioactive principles, in particular propolis extract. The present composition is of value because it exhibits antimicrobial (antibacterial, antifungal, antiviral and antiprotozoal), wound healing, anti-inflammatory, antioxidising and moisturising properties. The composition according to the present invention can be used in pharmaceutical and cosmetic formulations, thus being useful for odontological treatments (of caries, gingivitis, periodontitis, bad breath, aphthae, oral stomatitis) and for the treatment of affections of the skin and mucous membranes. The present composition also contains biocompatible and biodegradable polymers that allow controlled release of the active principles. For this purpose, the product can be provided in the form of different formulations: spray, mouthwash, toothpaste, oral-base cream, lotions, creams, gels, inter alia. | 2014-12-25 |
20140377196 | Customizable topical skin care product with variable product to ingredient ratio - A user controlled, customizable topical skin care product comprising a topical skin care product, at least one separate ingredient that may be combined with said product, and a means for combining said product and said ingredient. This device allows users to customize the skin care product's product-to-ingredient ratio. | 2014-12-25 |
20140377197 | SUNCARE FORMULATIONS AND METHODS - Described are suncare compositions, comprising a transparent aqueous microemulsion of a suncare active and a monoalkyl glycerol ether or a diglycerol ether. | 2014-12-25 |
20140377198 | Methods, Compositions, And Kit For Whitening Hyper Pigmented Spots On Skin - A skin whitening composition comprising a liquid polymeric coating material that, upon exposure to ambient air and moisture in skin, hardens to a water resistant, water vapor permeable, adherent and conformable solid film when applied to skin, and at least one skin whitening active; and a method and kit for whitening skin. | 2014-12-25 |
20140377199 | OIL-RICH AQUEOUS COMPOSITION AND ITS USE IN AN OXIDATIVE COLOURING OR BLEACHING METHOD - The present invention therefore relates in particular to an aqueous cosmetic composition comprising one or more fatty substances in a content ranging from 40% to 80% by weight, relative to the total weight of the cosmetic composition, one or more oxyethylenated fatty alcohols having a number of oxyethylenes less than or equal to 10, one or more alkylpolyglucoside-type surfactants; the present invention also relates to using the cosmetic composition in an oxidative colouring or bleaching method for keratin fibres, particularly human keratin fibres such as hair. | 2014-12-25 |
20140377200 | METHODS AND COMPOSITIONS FOR ALTERATION OF SKIN PIGMENTATION - Compositions are provided that possess levels of phytic acid and optionally a hydroxy acid and/or azelaic acid that act synergistically with the phytic acid to reduce melanin levels in skin. Improved reduction in melanin levels and hyperpigmentation are achieved at low levels of azelaic acid and phytic acid such that greater comfort and reduced irritation are observed at an administration site. Processes of reducing melanin levels or treating hyperpigmentation are provided by topically administering compositions of the invention. | 2014-12-25 |
20140377201 | SKIN-WHITENING COMPOSITION CONTAINING EXTRACTS FROM TREES INCLUDING PAPER MULBERRY - Disclosed is a skin-whitening composition comprising a paper mulberry extract, and more particularly to a skin-whitening composition containing an extract of | 2014-12-25 |
20140377202 | AQUEOUS LIQUID COSMETIC COMPOSITION COMPRISING ALKYLCELLULOSE, NON-VOLATILE OILS AND AT LEAST ONE SURFACTANT - The present invention relates to a liquid cosmetic composition comprising, in a physiologically acceptable medium: at least 20% of water, at least alkylcellulose, preferably at least 1% of alkylcellulose, at least one first hydrocarbon-based non-volatile oil, chosen from: C | 2014-12-25 |
20140377203 | AQUEOUS COSMETIC COMPOSITION COMPRISING ALKYLCELLULOSE, NON-VOLATILE OILS, AT LEAST ONE WAX AND AT LEAST ONE PARTICULAR HYDROPHILIC GELLING AGENT - The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium: —at least water, —at least alkylcellulose, —at least one first hydrocarbon-based non-volatile oil, chosen from: —C | 2014-12-25 |
20140377204 | COMPOSITIONS FOR KERATINOUS FIBRES, COMPRISING A CELLULOSE WITH CATIONIC STRUCTURAL UNIT AND A SPECIFIC COPOLYMER - An agent is provided for treating keratin-containing fibers, in particular human hair, comprising (a) a cellulose with a cationic structural unit and (b) a copolymer comprising a structural unit of formula (A1), a structural unit of formula (A2) and a structural unit of formula (A3), in which R | 2014-12-25 |
20140377205 | METHOD OF PREPARING HAIR CONDITIONING COMPOSITION COMPRISING POLYOL - Disclosed is a method of preparing a hair conditioning composition, wherein the composition comprising a cationic surfactant, a high melting point fatty compound, and a polyol having a molecular weight of from about 40 to about 500, and wherein the method comprises a step of mixing the cationic surfactant system, high melting point fatty compound, and polyol, to form an emulsion. The composition preferably further comprises an aqueous carrier, and the aqueous carrier is preferably mixed with other ingredients to form an emulsion. | 2014-12-25 |
20140377206 | SYSTEM USE OF SHAMPOO AND HAIR CONDITIONING COMPOSITION COMPRISING MONO-LONG ALKYL AMINE AND/OR POLYOL - Disclosed is a system of a hair shampoo composition and a hair conditioner composition, wherein the shampoo composition comprises a higher molecular weight and/or higher charge density cationic polymer, and wherein the conditioning composition comprises a cationic surfactant being an mono-long alkyl amine cationic surfactant and/or a polyol having a molecular weight of from about 40 to about 500. The system provides improved cleanness of the hair. | 2014-12-25 |
20140377207 | ABSORBENT ARTICLE COMPRISING COMPLEXED OR ENCAPSULATED REACTIVE COMPOUNDS - Absorbent articles comprising one or more complexed or encapsulated compounds compounds selected from: melonal, adoxal, trans-2-hexenal, ligustral, Floral Super, Florhydral, 5-methyl-2-thiophene-carboxaldehyde, hydratropic aldehyde, undecenal, 9-undecenal, 10-undecenal, trans-4-decenal, cis-6-nonenal, isocyclocitral, precyclemone b, (E)-2,(z)-6-nonadienal, undecyl aldehyde, methyl-octyl-acetaldehyde, Lauric aldehyde, silvial, vanillin, floralozone; are particularly effective in reducing malodors coming from degradation of proteinaceous materials such as food, menses or feces. | 2014-12-25 |
20140377208 | NOVEL MANUFACTURING AND APPLICATIONS OF ADHESIVE MATERIALS - A novel method of manufacturing and applications of a composition of matter comprising of a cross-linked form of a polysaccharide, at least one cross-linking agent comprised of divalent ions for effecting said cross-linked form of said polysaccharide, and at least one synthetically prepared phloroglucinol compound selected from the group comprising of phloroglucinol, a derivative of phloroglucinol, and a polymer synthetically prepared from phloroglucinol or a derivative of phloroglucinol, as an adhesive in procedures for reattaching or repairing body parts or components thereof, such as tissue, of (human or animal) subjects, especially under wet conditions, for example, involving adhesion of wet surfaces. | 2014-12-25 |
20140377209 | SCAFFOLDS FORMED FROM POLYMER-PROTEIN CONJUGATES, METHODS OF GENERATING SAME AND USES THEREOF - Conjugates are provided herein which comprise a protein attached to at least two polymeric moieties, at least one of which exhibits reverse thermal gelation. The conjugates are suitable for being cross-linked by non-covalent and/or covalent cross-linking. Compositions-of-matter comprising cross-linked conjugates are provided herein, as well as processes for producing same. Methods of controlling a physical property of compositions-of-matter are also provided herein. The conjugates and compositions-of-matter may be used for various applications, such as cell growth, tissue formation, and treatment of disorders characterized by tissue damage or loss, as described herein. | 2014-12-25 |
20140377210 | ARTIFICIAL TEAR COMPOSITIONS - The invention provides artificial tear compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients. | 2014-12-25 |
20140377211 | In situ-formed bioactive tissue adherent films of absorbable crystallizable polymers - An in situ film-forming sprayable methyl acetate-based solution of at least one absorbable, low-crystallinity, segmented copolymer contains at least one bioactive agent, which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane and the bioactive solution thereof can be applied onto animal and human skin or accessible body cavities to prevent or treat one or more disorder susceptible to the bioactive agent therein. | 2014-12-25 |
20140377212 | CONFORMATIONS OF DIVERGENT PEPTIDES WITH MINERAL BINDING AFFINITY - A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function. | 2014-12-25 |
20140377213 | WET-ELECTROSPUN BIODEGRADABLE SCAFFOLD AND USES THEREFOR - A cell growth matrix is provided that comprises a biodegradable elastomeric polymer electrodeposited concurrently with a sprayed or electrosprayed liquid that is a physiological solution or which comprises a mammalian blood product such as serum, plasma or platelet rich plasma. The matrix is useful as a cell-growth matrix and for repair of a tissue in a mammal, for instance by implantation in a mammal at a site in need of repair, such as in an abdominal wall. | 2014-12-25 |
20140377214 | MATERIALS AND METHODS TO ENHANCE HEMATOPOIETIC STEM CELLS ENGRAFTMENT PROCEDURES - This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE | 2014-12-25 |
20140377215 | DELIVERY OF THERAPEUTIC AGENTS BY A COLLAGEN BINDING PROTEIN - Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided. | 2014-12-25 |
20140377216 | ANTICANCER FUSION PROTEIN - A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and at least one domain (b) which is a sequence of a cytolytic effector peptide forming pores in the cell membrane, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases. | 2014-12-25 |
20140377217 | Compositions for Preventing Cardiac Arrhythmia - Disclosed herein are compositions and methods for treating or preventing a cardiac arrhythmia in a subject. | 2014-12-25 |
20140377218 | HCV IMMUNOTHERAPY - The invention relates to the use of Interleukin-7 (IL-7), for treating hepatitis C in a patient infected with hepatitis C virus, wherein said patient has been treated or is being treated with an antiviral agent or a combination of antiviral agents that reduces viral load. | 2014-12-25 |
20140377219 | HIV INHIBITORS - Chemical compounds that inhibit retroviruses are presented herein. More particularly, this disclosure provides small molecule compounds that inhibit infection with, or treat infection caused by, human immunodeficiency viruses. | 2014-12-25 |
20140377220 | GENE EXPRESSION SIGNATURES FOR STAGING AND PROGNOSIS OF PROSTATE, BREAST AND LEUKEMIA CANCERS - The present invention is drawn to methods of assessing and treating cancers such as ERG-related, prostate, breast and leukemia, by examining the expression of combinations of particular genes disregulated in this disease state. The combinations of genes are selected from the following genes: inhibitor of growth family, member 3 (HSTG3); lymphoid enhancer-binding protein factor 1 (LEF1); frizzled-related protein (FRZB); annexin A4 (ANXA4); Meis homeobox 2 (MEIS2); syndecan binding protein (syntenin) (SDCBP); ankyrin 3, node of Ranvier (ankyrin G) (ANK3); chromodomain helicase DNA binding protein 5 (CHD5); phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) (PLA2G7); and wingless-type MMTV integration site family member 2 (WNT2). | 2014-12-25 |
20140377221 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION - The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy. | 2014-12-25 |
20140377222 | USE OF INTERLEUKIN-22 IN THE TREATMENT OF FATTY LIVER DISEASE - The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided. | 2014-12-25 |
20140377223 | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to novel Substituted Biphenylene Compounds of Formula (I): | 2014-12-25 |
20140377224 | Method of Treating or Retarding the Development of Blindness - A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method. | 2014-12-25 |
20140377225 | METHODS OF IMPROVING BONE HEALTH AND MUSCLE HEALTH - The present invention comprises a method of improving bone health and muscle health in a companion animal comprising administering a composition comprising a fatty acid component to the companion animal wherein the fatty acid component comprises a ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA) from about 3:1 to about 25:1. The present invention additionally comprises a composition comprising a fatty acid component comprising docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) wherein the ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA) is from about 3:1 to about 25:1. | 2014-12-25 |
20140377226 | Tissue Transplantation Involving, and Tissues Modified by Decellularization And Recellularization Of Donor Tissues For Minimized Or Obviated Rejection Reactions - The method of tissue transplantation involving recellularizing of a donor organ with the utilization of the recipient's cytokines collected from the recipient's blood plasma at less than systemic pressure, and at the temperature greater than freezing and less than normal systemic temperature of the recipient's blood. Specifically, a method of harvesting a platelet-derived growth factors from platelet rich plasma (PRP), the growth factors having increased weight. | 2014-12-25 |
20140377227 | Tissue Transplantation Involving, and Tissues Modified by Decellularization And Recellularization Of Donor Tissues For Minimized Or Obviated Rejection Reactions - The method of tissue transplantation involving recellularizing of a donor organ with the utilization of the recipient's cytokines collected from the recipient's blood plasma at less than systemic pressure, and at the temperature greater than freezing and less than normal systemic temperature of the recipient's blood. Specifically, a method of harvesting a platelet-derived growth factors from platelet rich plasma (PRP), the growth factors having increased weight. | 2014-12-25 |
20140377228 | Bone Marrow-Derived Cells Ameliorates The Pathological Consequences Of The Liver In Case Of Alpha1-Antitrypsin Deficiency - The present invention is based on the findings that bone marrow (BM)-derived progenitor cells more specifically mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs) and uncommitted hematopoietic cells (lin | 2014-12-25 |
20140377229 | METHODS AND COMPOSITIONS FOR TISSUE REGENERATION - A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vile, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, TGFα, and TNFα, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second vial. | 2014-12-25 |
20140377230 | Placental Stem Cell Populations - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 2014-12-25 |
20140377231 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS - The present disclosure concerns methods and compositions for differentiating cells, including adipose cells, into chondrocyte-like cells via in vitro, ex vivo, and/or in vivo mechanical strain. In particular aspects, adipose cells or re-differentiated adipose cells that are chondrocyte-like cells, are delivered to a joint or are shaped into cartilage. In some embodiments, the adipose cells may be delivered to a joint, such as an intervertebral disc, following which the cells differentiate into chondrocyte-like cells to treat dysfunction of cartilage therein, including to repair degenerated discs, for example. In certain aspects, the cells prior to delivery to the individual are managed in the absence of growth factors, in vitro mechanical strain, and/or matrix molecules, for example. | 2014-12-25 |
20140377232 | INNERVATION OF ENGINEERED STRUCTURES - Methods of generating an innervated muscle structures are disclosed as well as bioengineered structures for tissue repair or regeneration. The methods can include the steps of obtaining populations of smooth muscle cells and neuronal progenitor cells and then seeding the cells together onto a matrix material, followed by culturing the seeded cells to form an innervated smooth muscle cell construct of directionally oriented smooth muscle cells. In one embodiment, the neuronal progenitor cells can be seeded first as neurospheres in a biocompatible solution, e.g., a collagen/laminin solution, and allowed to gel. Next, a second suspension of smooth muscle cells can be deposited as separate layer. Multiple layer structures of alternating muscle or neuron composition can also be formed in this manner. Differentiation of the neuronal progenitor cells can be induced by exposure to a differentiation medium, such as Neurobasal A medium and/or exposure to a differentiating agent, such as B-27 supplement. The innervated muscle structures can be disposed around a tubular scaffold, e.g., a chitosan-containing tube and further cultured to form tubular, bioengineered structures and two or more innervated muscle structures can be joined together to form an elongate composite structure. | 2014-12-25 |
20140377233 | METHOD OF PREPARING AN ARTIFICIAL TOOTH PRIMORDIUM IN VITRO AND ARTIFICIALTOOTH PRIMORDIUM DERIVED THEREFROM - The present invention is directed to a method of preparing an artificial tooth primordium in vitro, comprising the steps: a) providing isolated mesenchymal dental pulp cells; and b) culturing the mesenchymal dental pulp cells under non-adherent conditions to form a cell aggregate representing an artificial tooth primordium; as well as to an artificial tooth primordium derived therefrom. | 2014-12-25 |
20140377234 | METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF - The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation. | 2014-12-25 |
20140377235 | METHODS FOR USING SYNTHETIC TRITERPENOIDS IN THE TREATMENT OF BONE OR CARTILAGE DISEASES OR CONDITIONS - The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions. | 2014-12-25 |
20140377236 | METHOD OF EFFICIENTLY CONVERTING NON-CARDIAC CELLS INTO CARDIOVASCULAR CELLS - Described herein is a method for generating cardiomyocytes (CMs) from non-cardiac cells. | 2014-12-25 |
20140377237 | Methods of Preparing Cells and Compositions - The present invention provides a method of preparing adult red blood cells from stem cells in vitro using certain transcription factors for use in medicine, transfusions and transplants. The invention also provides blood compositions with cells prepared by the method. | 2014-12-25 |
20140377238 | PROBIOTIC COMPOSITIONS AND METHODS - The present invention features compositions and methods for modulation of the mucosal immune system. The compositions include foods fermented by the probiotic organism, | 2014-12-25 |
20140377239 | ACTIVE AGENTS AGAINST PSEUDOMONAS SPECIES CAUSING ROTTING DISEASES IN MUSHROOM PRODUCTION, THEIR USE AND COMPOSITIONS CONTAINING THEM - A biological material is disclosed for exerting antagonism against the mushroom pathogen | 2014-12-25 |
20140377240 | METHODS AND COMPOSITIONS FOR EXPANDING IMMUNOSUPPRESSIVE T REGULATORY CELLS IN VITRO AND USES THEREOF - Disclosed herein are methods and compositions for expanding T-regulatory cells (“Treg” cells), resulting in “conditioned Treg cells.” Also disclosed herein are methods and compositions useful for modulating an autoimmune reaction and for treating or ameliorating immune-related diseases, disorders and conditions using the conditioned Treg cells. | 2014-12-25 |
20140377241 | BIOPREPARATION BALIS FOR THE PROPHYLAXIS AND TREATMENT OF INFECTIOUS DISEASES - Biotechnology and the creation of novel probiotic preparations based on the | 2014-12-25 |
20140377242 | COENZYME Q10-CONTAINING COMPOSITION FOR ORAL INGESTION - Disclosed are: a coenzyme Q10 composition for oral ingestion which improves the bioabsorbability of coenzyme Q10 and enables efficient ingestion of coenzyme Q10 and which is highly safe, and a pharmaceutical preparation and a functional food containing the composition for oral ingestion. Combining coenzyme Q10 and a seed processed product has made it possible to provide a coenzyme Q10-containing composition for oral ingestion excellent in bioabsorbability, and a pharmaceutical preparation and a functional food containing the composition for oral ingestion. | 2014-12-25 |
20140377243 | CELL-PENETRATING FUSION PROTEIN FOR REGENERATING OR PROLIFERATING STEM CELL - The present invention relates to a cell permeable fusion protein for strengthening regenerative potential of stem cells, and more particularly to a cell permeable fusion protein for strengthening regenerative potential of stem cells for stimulating the differentiation of stem cells, inhibiting apoptosis, maintaining the functionality of stem cells and restoring the stress-inhibited functionality of stem cells. | 2014-12-25 |
20140377244 | STABLE FORMULATIONS FOR CNS DELIVERY OF ARYLSULFATASE A - The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease). In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form. | 2014-12-25 |
20140377245 | METHODS AND COMPOSITIONS TO DETECT THE LEVEL OF LYSOSOMAL EXOCYTOSIS ACTIVITY AND METHODS OF USE - Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile. As such, the level of lysosomal exocytosis activity and/or lysosomal sialidase activity is predictive of a diagnosis and/or prognosis of cancer, chemotherapy resistance or dementia associated with Alzheimer's disease. | 2014-12-25 |
20140377246 | ENZYME REPLACEMENT THERAPY FOR TREATING MPS VII RELATED BONE LESIONS USING A CHEMICALLY MODIFIED ENZYME - The invention relates to a method of treating mucopolysaccharidoses using enzyme replacement therapy with chemically modified lysosomal enzymes. More specifically the method relates to administering chemically modified lysosomal enzymes intraperitoneal injection. In addition, the invention relates to treating type VII mucopolysaccharidoses or mucopolysaccharidoses type VII related bone lesions with a chemical modified β-glucuronidase, wherein the modified β-glucuronidase may be administered 5 weeks after birth, and or may be administered intraperitoneally. | 2014-12-25 |